Abstract:BackgroundTumorigenicity represents a critical challenge in stem cell-based therapies requiring rigorous monitoring. Conventional approaches for tumorigenicity evaluation are based on animal models and have numerous limitations. Brain organoids, which recapitulate the structural and functional complexity of the human brain, have been widely used in neuroscience research. However, the capacity of brain organoids for tumorigenicity evaluation needs to be further elucidated.MethodsA cerebral organoid model produced from human pluripotent stem cells (hPSCs) was employed. Meanwhile, to enhance the detection sensitivity for potential tumorigenic cells, we created a glioblastoma-like organoid (GBM organoid) model from TP53-/-/PTEN-/- hPSCs to provide a tumor microenvironment for injected cells. Midbrain dopamine (mDA) cells from human embryonic stem cells were utilized as a cell therapy product. mDA cells, hPSCs, mDA cells spiked with hPSCs, and immature mDA cells were then injected into the brain organoids and NOD SCID mice. The injected cells within the brain organoids were characterized, and compared with those injected in vivo to evaluate the capability of the brain organoids for tumorigenicity evaluation. Single-cell RNA sequencing was performed to identify the differential gene expression between the cerebral organoids and the GBM organoids.ResultsBoth cerebral organoids and GBM organoids supported maturation of the injected mDA cells. The hPSCs and immature mDA cells injected in the GBM organoids showed a significantly higher proliferative capacity than those injected in the cerebral organoids and in NOD SCID mice. Furthermore, the spiked hPSCs were detectable in both the cerebral organoids and the GBM organoids. Notably, the GBM organoids demonstrated a superior capacity to enhance proliferation and pluripotency of spiked hPSCs compared to the cerebral organoids and the mouse model. Kyoto Encyclopedia of Genes and Genomes analysis revealed upregulation of tumor-related metabolic pathways and cytokines in the GBM organoids, suggesting that these factors underlie the high detection sensitivity for tumorigenicity evaluation.ConclusionsOur findings suggest that brain organoids could represent a novel and effective platform for evaluating the tumorigenic risk in stem cell-based therapies. Notably, the GBM organoids offer a superior platform that could complement or potentially replace traditional animal-based models for tumorigenicity evaluation.

Sonic hedgehog medulloblastoma cells in co-culture with cerebellar organoids converge towards in vivo malignant cell states

Developmental basis of SHH medulloblastoma heterogeneity

Author Correction: Failure of Human Rhombic Lip Differentiation Underlies Medulloblastoma Formation

PTCH1 -mutant human cerebellar organoids exhibit altered neural development and recapitulate early medulloblastoma tumorigenesis

MDB-25. ESTABLISHING A NOVEL CEREBELLAR ORGANOID MODEL FOR INVESTIGATING HEREDITARY PREDISPOSITION TO CHILDHOOD BRAIN CANCER

Single-cell Transcriptomic Sequencing Identifies Subcutaneous Patient-Derived Xenograft Recapitulated Medulloblastoma

Sustained Hedgehog Signaling in Medulloblastoma Tumoroids is Attributed to Stromal Astrocytes and Astrocyte-Derived Extracellular Matrix

The transcriptional landscape of Shh medulloblastoma

scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy

Human Fetal Cerebellar Cell Atlas Informs Medulloblastoma Origin and Oncogenesis

Tmic-33. Microenvironment-Driven Changes In Glioblastoma Cell State Signatures Examined Using Region-Specific Human Brain Organoids

Glioblastoma-cortical organoids recapitulate cell state heterogeneity and intercellular transfer

Epco-01. From Hierarchy To Geography: Multi-Clones Drive The Cellular Diversity And Evolution Of Human Medulloblastoma

A Tumorigenicity Evaluation Platform for Cell Therapies Based on Brain Organoids

Stem-20. Multi-Omics Of Human Medulloblastomas And Genetic Lineage Tracing In Vivo Indicate Cellular Plasticity

Modeling Glioma Intratumoral Heterogeneity with Primary Human Neural Stem and Progenitor Cells

Identifying new biomarkers of aggressive Group 3 and SHH medulloblastoma using 3D hydrogel models, single cell RNA sequencing and 3D OrbiSIMS imaging

Ezh2 Delays Activation of Differentiation Genes During Normal Cerebellar Granule Neuron Development and in Medulloblastoma

Tmod-28. Modeling Microenvironmental Dynamics: A Novel 3D Glioma-Neuron Fusion Model

Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades During Tumorigenesis and Relapse

270 Inducing Neural Maturation and Increasing Survival in SHH Medulloblastoma Using EZH2 Inhibition in a Mouse Model